AstraZeneca will record sales in other countries worldwide, for which profits shared with Daiichi Sankyo will be recorded within cost of sales. Daiichi Sankyo will manufacture and supply DS-1062.
Following this approval for Enhertu in the U.S., AstraZeneca is due $175 million as a milestone payment to Daiichi Sankyo. Daiichi Sankyo recognizes Enhertu sales in the U.S. AstraZeneca reports ...
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval for their second antibody-drug conjugate (ADC) cancer treatment, Datroway, the partners have secured a seventh nod for their ...
(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...
The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) as the first HER2-directed therapy for adult patients with unresectable or metastatic hormone receptor ...
AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...
Daiichi Sankyo (OTCPK:DSKYF ... Agency (EMA), endorsed its antibody-drug conjugate Dato-DXd marketed with AstraZeneca (NASDAQ:AZN) as a late-line option for certain cases of breast cancer.
Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera ...
A new European survey sponsored by AstraZeneca (AZ) and Daiichi Sankyo has revealed widespread misconceptions about breast cancer and metastatic cases of the disease. The online questionnaire gathered ...
AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...
Trump tariffs on chips and drugs would hit U.S. allies in Asia Worldcategory· January 28, 2025 The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's ...